serve more people with LAL-D and HPP

We began 2019 with a solid foundation of science, innovation and a willingness to expand beyond our core areas of focus in order to better serve people living with rare diseases. Our objectives reflected an ambition to expand our leadership in rare disease with our existing medicines and new medicines to create meaningful value for all our stakeholders. Through the hard work and dedication of our colleagues across the globe, we delivered on those objectives and in turn, furthered our mission of transforming the lives of people affected by rare and devastating diseases.

6 regulatory approval and 7 business development transactions and 800+ new employees
Neurology in now alexion's largest franchise in the U.S.
ULTOMIRIS in now the market leader and standard of care